Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
Authors:
- Lsl Line Stensig LynggaardLLLsl Line Stensig Lynggaard
- Cecilie Utke RankCRCecilie Utke Rank
- Sofie Gottschalk HøjfeldtSHSofie Gottschalk Højfeldt
- Louise Tram HenriksenLHLouise Tram Henriksen
- Kirsten Brunsvig JarvisKJKirsten Brunsvig Jarvis
- Susanna RantaSRSusanna Ranta
- Riitta NiinimäkiRNRiitta Niinimäki
- Thomas Leth FrandsenTFThomas Leth Frandsen
- Mats HeymanMHMats Heyman
Open Access
- 4 January 2022
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (1) , 138-147
Abstract
Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized protocol compliance and compromises survival. We investigated the association between risk of asparaginase-associated toxicities (AspTox) and asparaginase enzyme activity (AEA) levels in 1155 children aged 1.0 to 17.9 years, diagnosed with ALL between July 2008 and March 2016, and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. Patients with ≥2 blood samples for AEA measurement drawn 14 ± 2 days after asparaginase administration were included (6944 trough values). AEA was measurable (or >0 IU/L) in 955 patients, whereas 200 patients (17.3%) had asparaginase inactivation and few AspTox recorded. A time-dependent multiple Cox model of time to any first asparaginase-associated toxicity adjusted for sex and age was used. For patients with measurable AEA, we found a hazard ratio (HR) of 1.17 per 100 IU/L increase in median AEA (95% confidence interval [CI], 0.98-1.41; P = .09). For pancreatitis, thromboembolism, and osteonecrosis, the HRs were 1.40 (95% CI, 1.12-1.75; P = .002), 0.99 (95% CI, 0.70-1.40; P = .96), and 1.36 (95% CI, 1.04-1.77; P = .02) per 100 IU/L increase in median AEA, respectively. No significant decrease in the risk of leukemic relapse was found: HR 0.88 per 100 IU/L increase in AEA (95% CI, 0.66-1.16; P = .35). In conclusion, these results emphasize that overall AspTox and relapse are not associated with AEA levels, yet the risk of pancreatitis and osteonecrosis increases with increasing AEA levels.Keywords
This publication has 44 references indexed in Scilit:
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaBlood, 2011
- The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocolsBritish Journal of Haematology, 2011
- Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)Leukemia, 2009
- Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2008
- Thrombosis and acute lymphoblastic leukaemiaBritish Journal of Haematology, 2007
- Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium ProtocolsJournal of Clinical Oncology, 2007
- Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patientsBlood, 2006
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2004
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001